VICE PRESIDENT, INDUSTRY RESEARCH, BIOTECHNOLOGY INNOVATION ORGANIZATION
Washington, United States
David covers investment, R&D and alliance deal trends as well as regulatory statistics that impact policy initiatives in Washington. Prior to joining BIO, David spent over a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. David is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.
2:00 PM - 2:45 PM (EDT)
Monday, June 14
David Thomas, BIO’s Vice President of Industry Analysis, will provide an overview of new investment…